EpiVacCorona

Last updated

EpiVacCorona
Foto upakovki EpiVakKorony.tif
Package of "EpiVacCorona" vaccine
Vaccine description
Target SARS-CoV-2
Vaccine type Peptide subunit
Clinical data
Trade names EpiVacCorona
Other namesEpiVacCorona-N, [1] Aurora-CoV [1]
Routes of
administration
Intramuscular
ATC code
  • None
Legal status
Legal status
  • RU: Registered on 14 October 2020
Full list of EpiVacCorona authorizations
Identifiers
DrugBank

EpiVacCorona (Russian:ЭпиВакКорона, tr. EpiVakKorona) is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. [2] [3] [4] It consists of three chemically synthesized peptides (short fragments of a viral spike protein) that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants. [5]

Contents

The interim results of the Phase III study were expected to be announced in the early 2021 or beginning of 2022. [6] According to the vaccine developers, the peptides and the viral part of the chimeric protein should immunize people who received this vaccine against SARS-CoV-2 and trigger the production of protective antibodies.

Some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens. [7] [8] In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts [9] [10] and criticism by some experts. [7] [11] [8] [12] [13] Meanwhile, the EpiVacCorona has received vaccine emergency authorization in a form of government registration in Russia and is available for vaccination outside the clinical trials. [14] The vaccine delivered via intramuscular route and aluminum hydroxide serves as an immunological adjuvant.

Pharmacology

Origin of EpiVacCorona antigenes EpiVacCorona design.tif
Origin of EpiVacCorona antigenes

According to the developers’ publications, [15] vaccine antigens are three peptides of the spike protein and a chimeric protein consisting of two parts (viral nucleocapsid protein and bacterial maltose-binding protein). In addition, the polyhistidine-tag - a short peptide that is introduced into a vaccine composition to purify a chimeric protein from a bacterial lysate - is also a vaccine antigen against which antibodies can form in those who have received the vaccine. A person vaccinated with EpiVacCorona can develop antibodies not only to the peptides of the spike protein, but also to other antigens present in the vaccine. According to Anna Popova who is a head of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare, it takes 42 days for those vaccinated with EpiVacCorona to develop immunity. [16]

The vaccine includes three chemically synthesized short fragments of the viral spike protein - peptides, which, according to the developers of EpiVacCorona represent the protein regions containing B-cell epitopes that should be recognized by the human immune system.

These peptides are represented by following amino acid sequences:

1) CRLFRKSNLKPFERDISTEIYQAGS, 2) CKEIDRLNEVAKNLNESLIDLQE, 3) CKNLNESLIDLQELGKYEQYIK. [2] [17]

In the vaccine all peptides are conjugated to a carrier protein, which is an expression product of the chimeric gene. This chimeric gene was created by fusion of two genes originating from different organisms, namely a gene encoding a viral nucleocapsid protein and a gene encoding a bacterial maltose-binding protein (MBP). The fusion chimeric gene expressed in Escherichia coli . The sequence of the chimeric protein is available from the patent. The genetic construct of the chimeric gene also includes a short genetic fragment encoding a polyhistidine-tag, which is used to purify the chimeric protein from E. coli lysate. After the purification, the protein is conjugated with three peptides in a way that only one variant of the peptide molecule is attached to each protein molecule. As a result, three types of conjugated molecules are created: chimeric protein with attached peptide number 1, the same protein with peptide number 2, and finally the same protein with peptide number 3. All three types of conjugated molecules are included in the vaccine.[ citation needed ]

EpiVacCorona: antigens origin and composition EpiVacCorona in illustrations.tif
EpiVacCorona: antigens origin and composition

History

Clinical trials

Immunogenic peptide screening in rabbits for EpiVacCorona design Rabbits antibody detection scheme.tif
Immunogenic peptide screening in rabbits for EpiVacCorona design

Preclinical studies

The primary screening of peptides for the search for the most immunogenic ones was carried out in animals. The level of antibodies that was triggered by each tested peptide after administration to rabbits was measured. In the test, hemocyanin protein was used as a carrier protein for the studied peptides. Further, on six species of animals (mice, rats, rabbits, African green monkeys, rhesus monkeys, guinea pigs), the vaccine was shown to be harmless in terms of such parameters as general toxicity, allergic properties, and mutagenic activity. In four species of animals (hamsters, ferrets, African green monkeys, rhesus monkeys), specific activity was shown: immunogenicity and protective properties against SARS-CoV-2. The main results of preclinical studies are published in the "Bulletin of the Russian Academy of Medical Sciences". [17]

Clinical studies

The studies development timeline was reported in Russian media in January 2021. [18] There are currently two clinical trials of EpiVacCorona registered in the ClinicalTrials.gov database. [19] [20] [5]

Phase I-II

The trial "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)" [20] was registered in clinical trial database with ClinicalTrials.gov identifier: NCT04780035. Another trial with the same title was registered with ClinicalTrials.gov Identifier: NCT04527575. Results of the trial that included data on 86 participants were published in Russian Journal of Infection and Immunity, indicating preliminary evidence of safety and an immune response. [2] The publication reports preliminary results of the first two phases of clinical trials of the vaccine in volunteers, of which 14 people aged 18-30 years participated in the first phase, and 86 volunteers aged 18-60 years in the second phase. It is claimed that antibodies were formed in 100% of the volunteers, and the vaccine is also claimed to be safe. [2]

Phase III

The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants planned. It is expected to be completed in September 2021. [5] In the clinical trials database the phase III trial etitled "Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 [5] " was registered only in March 2021 with ClinicalTrials.gov Identifier: NCT04780035. Phase 3-4 trial was registered in Russia at 18.11.2020 with 4991 participants planned. [21]

Authorization

  Full authorization
  Emergency authorization

The VECTOR has received vaccine emergency authorization in a form of government registration in October 2020. [22]

In Russia phase III clinical study is called post-registration study. Therefore, government registration of the vaccine means permission to perform phase III clinical research and public vaccination outside of clinical trials as well. [22] Since December 2020, the vaccine has been released for public vaccination in Russia. [23]

As of March 2021, Turkmenistan is the only foreign state to register EpiVacCorona with full authorization. [24] [25]

Russia's Chief Health Officer Anna Popova said: "In December 2020 the EpiVacCorona documents were presented to the World Health Organization, and we are expecting a decision from WHO." [26] However, Deutsche Welle reports "As of March 1, the WHO had yet to receive an Expression of Interest (EOI) from EpiVacCorona's developers, "VECTOR," to enable WHO experts to evaluate their vaccine." [27]

Society and culture

Economics

The Deputy Director-General of the World Health Organization (WHO) Dr. Soumya Swaminathan during news conference in Geneva that took place in October 2020, told: "We will only be able to have a position on a vaccine when we see results of the phase III clinical trials." [28] The interim results of the Phase III study are expected to be announced in late 2021 or early 2022. Therefore the protective efficacy of the vaccine is currently unknown (July 2021). According to the center's director Rinat Maksyutov, many government and non-government organizations want to test or be involved in the production of the vaccine. [29] As of March 30, Venezuela obtained 1000 doses of the Russian EpiVacCorona vaccine for a trial. [30] Venezuela also has reached a deal to purchase doses of the vaccine, as well as manufacture it locally, Vice President Delcy Rodriguez provided this information on June 4, 2021. [31] Turkmenistan expects to receive EpiVacCorona, as the vaccine has already been approved for use in that country. [32]

Intellectual property

The following patents of the Russian Federation for invention have been published, which protect the EpiVacCorona vaccine:

"Peptide immunogens and vaccine composition against coronavirus infection COVID-19 using peptide immunogens" (No. 2738081). There are 7 peptides in patented vaccine compositions.

"Peptide immunogens and vaccine composition against coronavirus infection COVID-19 using peptide immunogens" (No. 2743593). The patented vaccine composition contains 2 peptides.

"Peptide immunogens used as a component of a vaccine composition against coronavirus infection COVID-19" (No. 2743594). The patented vaccine composition contains 3 peptides.

"Vaccine composition against coronavirus infection COVID-19" (No. 2743595). The patented vaccine composition contains 3 peptides.

In all of these patents, the carrier protein is referred to as a chimeric fusion protein with an amino acid sequence derived from two parts, a bacterial maltose binding protein and a viral nucleocapsid protein.

Controversies

Independent study of clinical trial participants

At the start of the Phase III, trial participants and those vaccinated outside the trial began to form a community through the Telegram messenger network. On January 18, 2021, the members of the community turned to the Ministry of Health of the Russian Federation with an open letter, in which they stated that the production of antibodies after vaccination among them is much lower than declared by vaccine developers. [33] Study participants claimed that antibodies were not found in more than 50% of those who documented their participation in the study, although only 25% of the participants should have had a placebo according to the study design. The trial participants also claimed that negative results were obtained using the a special ELISA test developed and recommended by VECTOR for EpiVacCorona detection. [9] [10] [8]

More questions about the quality and protectiveness of antibodies induced by EpiVacCorona arose along with the first results of a special antibody VECTOR's test, when, with a positive special test, negative results of all other commercially available tests were obtained: LIAISON SARS-CoV-2 S1 / S2 IgG - DiaSorin, IgM / IgG - Mindray, SARS-CoV-2 IgG - Abbott Architect, Anti-SARS-CoV-2 ELISA (IgG) - Euroimmun, Access SARS-CoV-2 IgG (RBD) - Beckman Coulter, "SARS-CoV-2-IgG-ELISA -BEST "-" Vector-Best "," Anti-RBD IgG "- Gamaleya Research Center. [9] [10] [8] [11] Clinical trial participants conducted their own antibody mini-study that was performed in independent Russian laboratory. The study participants asked Dr. Alexander Chepurnov, the former head of the infectious diseases department at VECTOR, who now works at another medical institute, to check neutralizing antibodies presence in their serum samples. [7] They also sent to Dr. Chepurnov control serum samples from former COVID-19 patients or people vaccinated with another Russian vaccine, Sputnik V, which is known to trigger the production of neutralizing antibodies. [34] All serum samples were blinded before antibody tests. On 23 March 2021, the participants reported the results of their mini-study in an open letter to the Ministry of Health of the Russian Federation. [10] [35] According to the letter, even with the help of the VECTOR antibody detection system, antibodies were detected only in 70-75% of those vaccinated with EpiVacCorona. However, the level of antibodies was very low. Moreover, according to the letter, virus-neutralizing antibodies were not detected in the independent research Dr. Alexander Chepurnov laboratory at all. [7] [10] [35] The trial participants asked Ministry of Health in their open letter to perform independent study for the verification of their findings. [7] [10] [35] In addition, the letter reports 18 cases of COVID-19 cases as of March 22, 2021 among those who received the vaccine and became ill (sometimes severe) three weeks or later after the second dose of EpiVacCorona. [36] [10] [35] April 20, 2021 the study participants got a reply, with refusal of performing any additional verification antibody tests or investigation of severe COVID-19 cases among vaccinated individuals. The reply include the following text: "Considering that the listed immunobiological preparations (vaccines) for the prevention of COVID-19 are registered in the prescribed manner, their effectiveness and safety have been confirmed."

Vaccine criticism by independent experts

Some independent experts criticized the vaccine design [7] [8] and clinical data presentation in the publication. [11] [12] [13] The experts are saying that peptide selection is "crucial" for the innovative peptide approach, which VECTOR uses for EpiVacCorona design. However, some researchers are not convinced that the viral spike protein peptides selected for the vaccine are actually "visible" by human immune system. [7] [8] They stated that these peptides do not overlap [37] with peptides that have been shown in several publications to contain human linear B cell epitopes in spike protein of SARS-CoV-2. [38] [39] [40] [41] [42] Moreover, the study was criticized for the lack of positive control of convalescent plasma samples in reports related to neutralizing antibody titers in vaccinated individuals. [2] [13] The same study was also criticized for presence of detectable antibodies in negative controls samples that were not discussed by authors. [2] [13] Conventional commercially available antibody detection systems cannot reveal post vaccination antibodies after EpiVacCorona. [9] [10] [8] [11] Therefore, vaccine developers have designed their own detection test system, and they were criticized for not revealing antigens in this system. Thus, some researchers have suggested that this test system may detect antibodies to certain vaccine antigens not associated with the SARS-CoV-2 virus, such as maltose binding protein (MBP), which is part of the vaccine carrier chimeric protein. [43] In addition, vaccine developers have been criticized for aggressively advertising their vaccine efficacy prior to the completion of phase III clinical trial. The most substantial criticism came from Dr. Konstantin Chumakov, who currently serves as the Associate Director for Research at the FDA Office of Vaccines Research and Review. Dr. Chumakov said: "I would not be in a hurry to call this peptide formulation a vaccine yet, because its effectiveness has not yet been proven...For the introduction of such a vaccine, the level of evidence must be much higher, and therefore the developers of EpiVacCorona, before launching their vaccine on the market, had to conduct clinical trials and prove that their vaccine actually protects against the disease. However, such tests were not carried out, which is absolutely unacceptable." [44]

Conflict of interest

The vaccine design was protected by several already issued patents (see section above). In each patent one of its co-authors is a namesake of Anna Popova who is the head of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare. [45] [46] This patent authorship represents an issue as far as Anna Popova is a head of the Russian agency that is charged with overseeing vaccine safety and efficacy. As a co-author of these patents, she might have an interest in promoting the vaccine despite its shortcomings.

Related Research Articles

Peptide-based synthetic vaccines, also called epitope vaccines, are subunit vaccines made from peptides. The peptides mimic the epitopes of the antigen that triggers direct or potent immune responses. Peptide vaccines can not only induce protection against infectious pathogens and non-infectious diseases but also be utilized as therapeutic cancer vaccines, where peptides from tumor-associated antigens are used to induce an effective anti-tumor T-cell response.

Universal flu vaccine Vaccine that prevents infection from all strains of the flu

A universal flu vaccine is a flu vaccine that is effective against all influenza strains regardless of the virus sub type, antigenic drift or antigenic shift. Hence it should not require modification from year to year. As of 2021 no universal flu vaccine had been approved for general use, several were in development, and one was in clinical trial.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

Convidecia Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

Sputnik V COVID-19 vaccine Vaccine against COVID-19

Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.

CoronaVac Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as BBIBP-CorV, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.

ZF2001 Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

CureVac COVID-19 vaccine Vaccine candidate against COVID-19

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.

CoviVac is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre, which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It obtained a permission for phase III clinical trial on 2 June 2021.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

Sanofi–GSK COVID-19 vaccine Vaccine candidate against COVID-19

The Sanofi–GSK COVID-19 vaccine code-named VAT00002 and VAT00008 is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.

Nanocovax Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

UB-612 Vaccine candidate against COVID-19

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical, Inc. Asia, Vaxxinity, and DASA. It is a peptide vaccine.

Viral vector vaccine Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material coding for a desired antigen into the recipient's host cells. As of April 2021, six viral vector vaccines have been authorized for use in humans in at least one country: four COVID-19 vaccines and two Ebola vaccines.

West China Hospital COVID-19 vaccine Vaccine candidate against COVID-19

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.

TurkoVac Vaccine candidate against COVID-19

TURKOVAC is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.

Sputnik Light Vaccine against COVID-19

Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.

COVI-VAC (U.S. COVID-19 vaccine) Vaccine candidate against COVID-19

COVI-VAC is a COVID-19 vaccine being developed by Codagenix, Inc. It is currently in Phase I clinical trials, involving 48 participants which runs from December 2020 to June 2021.

GBP510 Vaccine candidate against COVID-19

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. 24 vaccines are authorized for use by national governments, including six approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

References

  1. 1 2 "EpiVacCorona-N COVID-19 vaccine to be registered under Aurora-CoV brand name". Russian News Agency. 5 July 2021. Retrieved 6 July 2021.
  2. 1 2 3 4 5 6 Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Danilenko ED, Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov SA, Tregubchak TV, Antonec DV, Gavrilova EV, Maksyutov RA (2021). "A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)". Russian Journal of Infection and Immunity. 11 (2): 283–296. doi: 10.15789/2220-7619-ASB-1699 .
  3. Ryzhikov, Aleksandr & Ryzhikov, Alexander & Bogryantseva, Marina & Danilenko, Elena & Imatdinov, Ilnaz & Nechaeva, Elena & Pyankov, Oleg & Pyankova, Olga & Susloparov, Ivan & Taranov, Oleg & Gudymo, Andrei & Danilchenko, Natalya & Sleptsova, Ekaterina & Bodnev, Sergey & Onkhonova, Galina & Petrov, Vladimir & Moiseeva, Anastasiya & Torzhkova, Polina & Pyankov, Stepan & Maksyutov, Rinat. (2021). Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2. Annals of the Russian academy of medical sciences. 76. 5-19. 10.15690/vramn1528. https://www.researchgate.net/publication/350822775_Immunogenicity_and_protectivity_of_the_peptide_candidate_vaccine_against_SARS-CoV-2
  4. https://vestnikramn.spr-journal.ru/jour/article/view/1528
  5. 1 2 3 4 Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (2 March 2021). "Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)".Cite journal requires |journal= (help)
  6. "Промежуточные результаты III фазы исследований "Спутника V" опубликуют осенью". Interfax.ru (in Russian). Retrieved 15 October 2021.
  7. 1 2 3 4 5 6 7 DobrovidovaApr. 6, Olga; 2021; Am, 11:05 (6 April 2021). "Russia's COVID-19 defense may depend on mystery vaccine from former bioweapons lab—but does it work?". Science | AAAS. Retrieved 24 April 2021.CS1 maint: numeric names: authors list (link)
  8. 1 2 3 4 5 6 7 Dobrovidova, Olga (9 April 2021). "Latest Russian vaccine comes with a big dose of mystery". Science. 372 (6538): 116–117. Bibcode:2021Sci...372..116D. doi:10.1126/science.372.6538.116. ISSN   0036-8075. PMID   33833104. S2CID   233191522.
  9. 1 2 3 4 Reuters Staff (26 March 2021). "Volunteers break rank to raise doubts in trial of Russia's second COVID-19 vaccine". Reuters. Retrieved 23 April 2021.
  10. 1 2 3 4 5 6 7 8 ""ЭпиВакКорона" глазами участников клинических испытаний и ученых-биологов". Троицкий вариант — Наука (in Russian). 23 March 2021. Retrieved 23 April 2021.
  11. 1 2 3 4 "EpiVacCorona's race to the finish line Meduza speaks to the developer and manufacturer about concerns surrounding Russia's latest coronavirus vaccine". meduza.io. Retrieved 23 April 2021.
  12. 1 2 "Нет антител, вопросы к составу, непрозрачность данных. Что не так с вакциной "ЭпиВакКорона"". BBC News Русская служба (in Russian). Retrieved 23 April 2021.
  13. 1 2 3 4 "Sputnik V's ugly cousin Clinical results for Russia's EpiVacCorona vaccine are finally here, but developers published in an obscure local journal, raising questions and concerns". meduza.io. Retrieved 23 April 2021.
  14. "About 200,000 EpiVacCorona vaccine doses go into civil circulation in Russia". TASS. Retrieved 25 April 2021.
  15. Ryzhikov, A. B.; Ryzhikov, Е. А.; Bogryantseva, M. P.; Usova, S. V.; Danilenko, E. D.; Nechaeva, E. A.; Pyankov, O. V.; Pyankova, O. G.; Gudymo, A. S. (24 March 2021). "A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)". Russian Journal of Infection and Immunity. Retrieved 23 April 2021.
  16. "People vaccinated with Russia's EpiVacCorona need 42 days to develop immunity - watchdog". TASS. Retrieved 25 April 2021.
  17. 1 2 Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Danilenko ED, Imatdinov IR, Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov SA, Tregubchak TV, Antonec DV, Sleptsova ES, Gavrilova EV, Maksyutov RA (2021). "Immunogenicity and Protectivityof the Peptide Vaccine againstSARS-CoV-2". Annals of the Russian Academy of Medical Sciences. 76 (1): 5–19. doi: 10.15690/vramn1528 .
  18. "Что ждать от "ЭпиВакКороны". Все о пептидной вакцине против COVID-19". РИА Новости (in Russian). 1 January 2021. Retrieved 24 April 2021.
  19. s.r.o, Direct Impact. "AIM database substance - EpiVacCorona". AIM. Retrieved 25 April 2021.
  20. 1 2 Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (20 February 2021). "Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)".Cite journal requires |journal= (help)
  21. Реестр Клинических исследований COV/pept-03/20;
  22. 1 2 "Russia begins post-registration trials of EpiVacCorona Covid-19 vaccine". www.clinicaltrialsarena.com. Retrieved 25 April 2021.
  23. "Вакцина "ЭпиВакКорона" поступила в гражданский оборот". РИА Новости (in Russian). 11 December 2020. Retrieved 23 April 2021.
  24. "Turkmenistan registers vaccines for the prevention of infectious diseases". Turkmenistan Today. 29 January 2021.
  25. "Turkmenistan: Master Berdymukhamedov goes to Moscow | Eurasianet". eurasianet.org. Retrieved 25 April 2021.
  26. "Russia submits EpiVacCorona vaccine documents to WHO - Rospotrebnadzor head Popova". interfax.com. Retrieved 23 April 2021.
  27. Welle (www.dw.com), Deutsche. "Two more Russian vaccines: What we do and don't know | DW | 09.03.2021". DW.COM. Retrieved 23 April 2021.
  28. "COVID-19 vaccine: WHO in talks with Russia on its second vaccine EpiVacCorona". mint. 16 October 2020. Retrieved 9 June 2021.
  29. "Vector Center says has over 45 inquiries from abroad about its EpiVacCorona vaccine". TASS. Retrieved 25 April 2021.
  30. Foundation, Thomson Reuters. "Venezuela receives doses of Russian EpiVacCorona vaccine for trials". news.trust.org. Retrieved 25 April 2021.
  31. "Venezuela to purchase and manufacture Russia's EpiVacCorona vaccine". Reuters. 5 June 2021. Retrieved 13 June 2021.
  32. turkmenportal. "Turkmenistan Approves Use of Russia's EpiVacCorona Vaccine | Society". Business Turkmenistan Information Center. Retrieved 25 April 2021.
  33. "«Мы хотим спасти людей от вакцины, если она неэффективна» . Отчет об эффективности «ЭпиВакКороны» по заказу «Вектора» готовит не биолог, а клинический психолог. Волонтеры требуют публикации данных" [«We want to save people, if the vaccine is ineffective». A report about «EpiVacCorona»'s efficacy ordered by «Vector» was prepared by a clinical psychiatrist, not by a biologist. Volunteers demand to publish data.]. Новая газета (in Russian). 31 July 2021. Retrieved 15 October 2021.
  34. Jones, Ian; Roy, Polly (20 February 2021). "Sputnik V COVID-19 vaccine candidate appears safe and effective". The Lancet. 397 (10275): 642–643. doi: 10.1016/S0140-6736(21)00191-4 . ISSN   0140-6736. PMC   7906719 . PMID   33545098.
  35. 1 2 3 4 https://epivakorona.com/openletter.htm
  36. "Участники КИ "ЭпиВакКороны" продолжают исследовать эффективность вакцины". pcr.news. Retrieved 24 April 2021.
  37. "Вакцина "ЭпиВакКорона" в иллюстрациях". Троицкий вариант — Наука (in Russian). 23 March 2021. Retrieved 24 April 2021.
  38. Yi, Zhigang; Ling, Yun; Zhang, Xiaonan; Chen, Jieliang; Hu, Kongying; Wang, Yuyan; Song, Wuhui; Ying, Tianlei; Zhang, Rong; Lu, HongZhou; Yuan, Zhenghong (December 2020). "Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population". Emerging Microbes & Infections. 9 (1): 1988–1996. doi:10.1080/22221751.2020.1815591. ISSN   2222-1751. PMC   7534331 . PMID   32844713.
  39. Poh, Chek Meng; Carissimo, Guillaume; Wang, Bei; Amrun, Siti Naqiah; Lee, Cheryl Yi-Pin; Chee, Rhonda Sin-Ling; Fong, Siew-Wai; Yeo, Nicholas Kim-Wah; Lee, Wen-Hsin; Torres-Ruesta, Anthony; Leo, Yee-Sin (1 June 2020). "Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients". Nature Communications. 11 (1): 2806. Bibcode:2020NatCo..11.2806P. doi:10.1038/s41467-020-16638-2. ISSN   2041-1723. PMC   7264175 . PMID   32483236.
  40. Li, Yang; Lai, Dan-Yun; Zhang, Hai-Nan; Jiang, He-Wei; Tian, Xiaolong; Ma, Ming-Liang; Qi, Huan; Meng, Qing-Feng; Guo, Shu-Juan; Wu, Yanling; Wang, Wei (October 2020). "Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients". Cellular & Molecular Immunology. 17 (10): 1095–1097. doi:10.1038/s41423-020-00523-5. ISSN   2042-0226. PMC   7475724 . PMID   32895485.
  41. Farrera-Soler, Lluc; Daguer, Jean-Pierre; Barluenga, Sofia; Vadas, Oscar; Cohen, Patrick; Pagano, Sabrina; Yerly, Sabine; Kaiser, Laurent; Vuilleumier, Nicolas; Winssinger, Nicolas (2020). "Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma". PLOS ONE. 15 (9): e0238089. Bibcode:2020PLoSO..1538089F. doi: 10.1371/journal.pone.0238089 . ISSN   1932-6203. PMC   7480855 . PMID   32903266.
  42. Shrock, Ellen; Fujimura, Eric; Kula, Tomasz; Timms, Richard T.; Lee, I.-Hsiu; Leng, Yumei; Robinson, Matthew L.; Sie, Brandon M.; Li, Mamie Z.; Chen, Yuezhou; Logue, Jennifer (27 November 2020). "Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity". Science. 370 (6520): eabd4250. doi:10.1126/science.abd4250. ISSN   1095-9203. PMC   7857405 . PMID   32994364.
  43. "Not all antibodies are equal: what is wrong with the EpiVacCorona vaccine". en.newizv.ru. Retrieved 5 July 2021.
  44. "Константин Чумаков: "Даже если человек переболел COVID-19, ему все равно нужно привиться. Иммунный ответ на прививку лучше и долговечнее, чем на саму болезнь"". republic.ru (in Russian). Retrieved 24 April 2021.
  45. "Операция "Э". Мы вам расскажем, что получает с "ЭпиВакКороной" человек, что — кролик, а что — разработчики вакцины. Исследование Ирины Тумаковой". Новая газета (in Russian). 3 June 2021. Retrieved 5 July 2021.
  46. "Глава Роспотребнадзора оказалась одним из разработчиков вакцины новосибирского "Вектора"". Континент Сибирь Online (in Russian). 4 June 2021. Retrieved 5 July 2021.